BACKGROUND: Study results on overall seroprevalence of Helicobacter pylori and colorectal cancer risk have been inconsistent. However, one study found positive associations with antibodies to specific H. pylori proteins. To follow up on those findings, we assessed associations of 15 H. pylori specific proteins with colorectal cancer incidence in the prospective Cancer Prevention Study-II Nutrition Cohort. MATERIALS AND METHODS: Participants in this nested case-control study included 392 cases and 774 controls who were predominantly elderly (median age at blood draw: 71 years) and Caucasian (98%). Seroreactivity against 15 H. pylori proteins was assessed by fluorescent bead-based multiplex serology and associations with colorectal cancer were estimated using conditional logistic regression. RESULTS: Helicobacter pylori serostatus was not associated with colorectal cancer incidence (odds ratio (OR), 1.17, 95% confidence interval (95% CI), 0.91-1.50). Among individual antigens, GroEl serostatus was associated with colorectal cancer risk (OR, 1.32, 95% CI: 1.03-1.70), whereas CagM was associated with colon cancer risk only (OR, 1.35, 95% CI: 1.01-1.80). No dose-response relationships were observed for any of the antigens, including GroEl and CagM. CONCLUSIONS: The results of our study do not support an association between H. pylori infection and colorectal cancer risk in this elderly, mostly Caucasian population.
BACKGROUND: Study results on overall seroprevalence of Helicobacter pylori and colorectal cancer risk have been inconsistent. However, one study found positive associations with antibodies to specific H. pylori proteins. To follow up on those findings, we assessed associations of 15 H. pylori specific proteins with colorectal cancer incidence in the prospective Cancer Prevention Study-II Nutrition Cohort. MATERIALS AND METHODS:Participants in this nested case-control study included 392 cases and 774 controls who were predominantly elderly (median age at blood draw: 71 years) and Caucasian (98%). Seroreactivity against 15 H. pylori proteins was assessed by fluorescent bead-based multiplex serology and associations with colorectal cancer were estimated using conditional logistic regression. RESULTS:Helicobacter pylori serostatus was not associated with colorectal cancer incidence (odds ratio (OR), 1.17, 95% confidence interval (95% CI), 0.91-1.50). Among individual antigens, GroEl serostatus was associated with colorectal cancer risk (OR, 1.32, 95% CI: 1.03-1.70), whereas CagM was associated with colon cancer risk only (OR, 1.35, 95% CI: 1.01-1.80). No dose-response relationships were observed for any of the antigens, including GroEl and CagM. CONCLUSIONS: The results of our study do not support an association between H. pyloriinfection and colorectal cancer risk in this elderly, mostly Caucasian population.
Authors: Julia Butt; Matthew G Varga; William J Blot; Lauren Teras; Kala Visvanathan; Loïc Le Marchand; Christopher Haiman; Yu Chen; Ying Bao; Howard D Sesso; Sylvia Wassertheil-Smoller; Gloria Y F Ho; Lesley E Tinker; Richard M Peek; John D Potter; Timothy L Cover; Laura H Hendrix; Li-Ching Huang; Terry Hyslop; Caroline Um; Francine Grodstein; Mingyang Song; Anne Zeleniuch-Jacquotte; Sonja Berndt; Allan Hildesheim; Tim Waterboer; Michael Pawlita; Meira Epplein Journal: Gastroenterology Date: 2018-10-06 Impact factor: 22.682
Authors: Nerea Fernández de Larrea-Baz; Angelika Michel; Beatriz Romero; Beatriz Pérez-Gómez; Victor Moreno; Vicente Martín; Trinidad Dierssen-Sotos; José J Jiménez-Moleón; Jesús Castilla; Adonina Tardón; Irune Ruiz; Rosana Peiró; Antonio Tejada; María D Chirlaque; Julia A Butt; Rocío Olmedo-Requena; Inés Gómez-Acebo; Pedro Linares; Elena Boldo; Antoni Castells; Michael Pawlita; Gemma Castaño-Vinyals; Manolis Kogevinas; Silvia de Sanjosé; Marina Pollán; Rosa Del Campo; Tim Waterboer; Nuria Aragonés Journal: Front Microbiol Date: 2017-05-29 Impact factor: 5.640